Hum. Reprod. Advance Access originally published online on April 2, 2009
Human Reproduction 2009 24(7):1732-1738; doi:10.1093/humrep/dep074
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-Müllerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome
1 Unit of Applied Clinical Research, Department of Cancer Research and Molecular Medicine, Norwegian University for Science and Technology, Olav Kyrres gate 9, 7489 Trondheim, Norway 2 Department of Laboratory Medicine, Children's and Women's Health, Norwegian University for Science and Technology, Olav Kyrres gate 9, 7489 Trondheim, Norway 3 Department of Endocrinology, St. Olavs Hospital, University Hospital of Trondheim, Trondheim, Olav Kyrres gate 17, 7006 Trondheim, Norway 4 Department of Obstetrics and Gynecology, St. Olavs Hospital, University Hospital of Trondheim, Trondheim, Olav Kyrres gate 17, 7006 Trondheim, Norway 5 Department of Developmental Medicine, University of Glasgow, Glasgow G31 2ER, UK
6 Correspondence address. Department of Endocrinology, St. Olavs Hospital, University Hospital of Trondheim, Olav Kyrres gate 17, N-7006 Trondheim, Norway. Tel: +47-73868042 or +47-73868567; Fax: +47-7386. E-mail: sven.carlsen{at}ntnu.no
BACKGROUND: Current data suggest that excessive androgen exposure can lead to the development of polycystic ovaries and polycystic ovary syndrome (PCOS). Anti-Müllerian hormone (AMH) levels reflect the number of small antral follicles in the ovaries and are elevated in PCOS. We hypothesized that protracted reduction of circulating androgens and/or insulin resistance would reduce circulating AMH concentrations in women with PCOS.
METHODS: A prospective, randomized, double-blind 26 week long study was undertaken in 50 women with PCOS. They all received diet and lifestyle counselling, and metformin 850 mg three times daily. Concomitantly, they were randomized to either dexamethasone 0.25 mg daily (n = 25) or placebo (n = 25). Thirty-eight women completed the study. AMH (primary outcome) and other hormone levels were measured at inclusion and after 8 and 26 weeks of treatment.
RESULTS: At baseline in univariate regression analyses, AMH levels associated positively with testosterone levels (P = 0.041) and ovarian volume (P = 0.002). In multivariate regression analyses, AMH associated positively with testosterone P = 0.004), and negatively with dehydroepiandrosterone sulphate (DHEAS) (P = 0.001) and C-peptide levels (P = 0.020). Circulating AMH concentrations were unaffected by 6 months of lifestyle counselling with metformin and placebo treatment. AMH levels were also unaffected by 6 months of androgen suppression with dexamethasone in addition.
CONCLUSIONS: AMH levels in untreated PCOS women associated positively with testosterone, and negatively with DHEAS and C-peptide levels. Six months of androgen suppression by either metformin or low-dose dexamethasone treatment failed to influence circulating AMH levels.
Key words: androgens/dexamethasone/anti-Müllerian hormone/polycystic ovary syndrome
Submitted on September 1, 2008; resubmitted on February 26, 2009; accepted on March 4, 2009.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. La Marca, G. Sighinolfi, D. Radi, C. Argento, E. Baraldi, A. C. Artenisio, G. Stabile, and A. Volpe Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART) Hum. Reprod. Update, September 30, 2009; (2009) dmp036v1. [Abstract] [Full Text] [PDF]
|
|